Cystatin C: A prognostic marker after myocardial infarction in patients without chronic kidney disease

被引:10
|
作者
Abid, Leila [1 ]
Charfeddine, Salma [1 ]
Kammoun, Samir [1 ]
Turki, Mouna [2 ]
Ayedi, Fatma [2 ]
机构
[1] Univ Hedi Chaker Hosp, Dept Cardiol, Sfax, Tunisia
[2] Habib Bourguiba Univ Hosp, Biochem Lab, Sfax, Tunisia
关键词
Cystatin C; Myocardial infarction; Cardiovascular mortality; Coronary artery disease; Major adverse cardiovascular events;
D O I
10.1016/j.jsha.2015.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Cystatin C is an endogenous marker of renal function. It is a well established better marker of glomerular filtration rate than serum creatinine. There is also evidence that cystatin C is associated with atherosclerotic disease. The present prospective study evaluated the prognostic value of cystatin C after myocardial infarction in patients without chronic kidney disease. Methods and results: A total of 127 patients who underwent coronary angiography after an acute coronary syndrome (ACS) were included. Cystatin C was associated with the severity of coronary artery disease (CAD). Cystatin C levels were significantly higher in patients with 3-vessels disease and severe CAD according to GENSINI score (p = 0.01 and p < 0.001 respectively). Among the patients admitted for ST elevation myocardial infarction, Cystatin C concentration was correlated with the initial TIMI flow in the culprit artery (p < 0.001). Mean duration of the follow-up period was 10.76 (sic) 2.1 months. High Cystatin C concentrations were associated to the occurrence of unfavourable outcomes and cardiovascular mortality during follow-up (1.19 (sic) 0.4 vs. 1.01 (sic) 0.35 mg/L, p = 0.01 and 1.21 (sic) 0.36 vs. 0.96 (sic) 0.27 mg/L, p = 0.03). Among different laboratory parameters, cystatin C was the best marker to predict the occurrence of major adverse cardiovascular events during the follow-up (Area under the receiveroperating characteristic curve = 0.743). Conclusion: High cystatin C levels are associated with the severity of coronary artery disease in patients presenting an acute coronary syndrome and a normal renal function. Cystatin C is also associated to unfavourable cardiovascular outcomes during follow-up and appears as a strong predictor for risk of cardiovascular events and death. (C) 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:144 / 151
页数:8
相关论文
共 50 条
  • [1] Prognostic value of silent myocardial infarction in patients with chronic kidney disease after kidney transplantation
    Santana, Julio C.
    Doppalapudi, Harish
    Ives, Christopher W.
    Farag, Ayman A.
    Rizk, Dana, V
    Kumar, Vineeta
    Iskandrian, Ami E.
    Hage, Fadi G.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (04) : 1115 - 1122
  • [2] Cystatin C and arterial stiffness in patients without chronic kidney disease
    Piko, Nejc
    Petreski, Tadej
    Naji, Franjo
    Ekart, Robert
    Hojs, Radovan
    Bevc, Sebastjan
    [J]. CLINICAL NEPHROLOGY, 2021, 96 (07) : S43 - S48
  • [3] The prognostic importance of cystatin C in severe systolic dysfunction without chronic kidney disease
    Ordu, Serkan
    [J]. ANNALS OF SAUDI MEDICINE, 2010, 30 (06) : 495 - 496
  • [4] Cystatin C and The Risk of Cardioembolic Stroke in Patients Without Chronic Kidney Disease
    Lee, Eung-Joon
    [J]. CEREBROVASCULAR DISEASES, 2018, 46 : 14 - 14
  • [5] Serum cystatin C as an endogenous marker of renal function in patients with chronic kidney disease
    Hojs, Radovan
    Bevc, Sebastjan
    Ekart, Robert
    Gorenjak, Maksimijan
    Puklavec, Ludvik
    [J]. RENAL FAILURE, 2008, 30 (02) : 181 - 186
  • [6] Cystatin C is a new marker for left ventricular hypertrophy in patients with chronic kidney disease
    Vasilyeva, M. P.
    Rudenko, T. E.
    Kutyrina, I. M.
    Solomakhina, N. I.
    [J]. TERAPEVTICHESKII ARKHIV, 2015, 87 (06): : 17 - 22
  • [7] The role of cystatin c in myocardial dysfunction in patients with chronic heart failure and chronic kidney disease
    Mykhailova, I.
    Kravchun, P.
    Lapshina, L.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 148 - 148
  • [8] Cystatin C and the Risk of Cardioembolic Stroke in Patients Without Chronic Kidney Disease.
    Lee, Eung-joon
    Jeong, Han-yeong
    Mo, Heejung
    Lee, Chan-hyuk
    Kang, Min Kyoung
    Kim, Tae Jung
    Ko, Sang-bae
    Yoon, Byung-woo
    [J]. STROKE, 2019, 50
  • [9] Prognostic implications of chronic kidney disease and anemia after percutaneous coronary intervention in acute myocardial infarction patients
    Yuya Matsue
    Akihiko Matsumura
    Masami Abe
    Maki Ono
    Mie Seya
    Tomofumi Nakamura
    Ryota Iwatsuka
    Akira Mizukami
    Masahiko Setoguchi
    Wataru Nagahori
    Masakazu Ohno
    Makoto Suzuki
    Yuji Hashimoto
    [J]. Heart and Vessels, 2013, 28 : 19 - 26
  • [10] Prognostic implications of chronic kidney disease and anemia after percutaneous coronary intervention in acute myocardial infarction patients
    Matsue, Yuya
    Matsumura, Akihiko
    Abe, Masami
    Ono, Maki
    Seya, Mie
    Nakamura, Tomofumi
    Iwatsuka, Ryota
    Mizukami, Akira
    Setoguchi, Masahiko
    Nagahori, Wataru
    Ohno, Masakazu
    Suzuki, Makoto
    Hashimoto, Yuji
    [J]. HEART AND VESSELS, 2013, 28 (01) : 19 - 26